Future of therapy for Hepatitis C in India: A Matter of Accessibility and Affordability?
作者信息
Dhiman Radha K
机构信息
Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India.
出版信息
J Clin Exp Hepatol. 2014 Jun;4(2):85-6. doi: 10.1016/j.jceh.2014.06.011.
Abstract
摘要
相似文献
1
Future of therapy for Hepatitis C in India: A Matter of Accessibility and Affordability?印度丙型肝炎治疗的未来：可及性与可负担性问题？
J Clin Exp Hepatol. 2014 Jun;4(2):85-6. doi: 10.1016/j.jceh.2014.06.011.
2
Accessibility, affordability and use of health services in an urban area in South Africa.南非某城市地区卫生服务的可及性、可负担性及使用情况
Curationis. 2015 Mar 10;38(1):102. doi: 10.4102/curationis.v38i1.102.
3
Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study.高收入、中等收入和低收入国家的糖尿病基本药物的可及性和可负担性：一项前瞻性流行病学研究。
Lancet Diabetes Endocrinol. 2018 Oct;6(10):798-808. doi: 10.1016/S2213-8587(18)30233-X. Epub 2018 Aug 28.
4
Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study.印度注射吸毒者中丙型肝炎病毒疾病负担及丙型肝炎病毒服务可及性：一项横断面研究。
Lancet Infect Dis. 2015 Jan;15(1):36-45. doi: 10.1016/S1473-3099(14)71045-X. Epub 2014 Dec 3.
5
Availability, Sales, and Affordability of Tobacco Cessation Medicines in Kerala, India.印度喀拉拉邦戒烟药物的可及性、销售量及可负担性
Circ Cardiovasc Qual Outcomes. 2017 Nov;10(11). doi: 10.1161/CIRCOUTCOMES.117.004108.
6
Future landscape of hepatitis C research - Basic, translational and clinical perspectives.丙型肝炎研究的未来前景 - 基础、转化和临床视角。
J Hepatol. 2016 Oct;65(1 Suppl):S143-S155. doi: 10.1016/j.jhep.2016.07.026.
7
[Cost-effectiveness and affordability of strategy for preventing mother-to-child transmission of hepatitis B in China].[中国预防乙型肝炎母婴传播策略的成本效益与可负担性]
Zhonghua Liu Xing Bing Xue Za Zhi. 2017 Jul 10;38(7):852-859. doi: 10.3760/cma.j.issn.0254-6450.2017.07.003.
8
Trans-Pacific Partnership Agreement and Its Impact on Accessibility and Affordability of Medicines: A Meta-synthesis.《跨太平洋伙伴关系协定及其对药品可及性和可负担性的影响：一项元综合分析》
Ther Innov Regul Sci. 2017 Jul;51(4):446-459. doi: 10.1177/2168479017697253. Epub 2017 Mar 28.
9
Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.30个国家丙型肝炎新药的价格、成本及可负担性：一项经济分析
PLoS Med. 2016 May 31;13(5):e1002032. doi: 10.1371/journal.pmed.1002032. eCollection 2016 May.
10
Measuring water affordability in developed economies. The added value of a needs-based approach.衡量发达经济体的水可负担能力。基于需求的方法的附加值。
J Environ Manage. 2018 Jul 1;217:611-620. doi: 10.1016/j.jenvman.2018.03.106. Epub 2018 Apr 9.
引用本文的文献
1
Preoperative viral screening in cataract surgery: Essential or excessive?白内障手术中的术前病毒筛查：必要还是过度？
Indian J Ophthalmol. 2025 Aug 1;73(8):1221-1222. doi: 10.4103/IJO.IJO_346_25. Epub 2025 Jul 28.
2
Decentralised same day test and treatment of hepatitis C levering existing peer support networks among men who inject drugs: feasibility and effectiveness.在注射吸毒者中利用现有的同伴支持网络进行丙型肝炎病毒检测和治疗：可行性和有效性。
Harm Reduct J. 2024 May 20;21(1):98. doi: 10.1186/s12954-024-01001-1.
3
Balancing uncertainty and proactivity in care seeking for hepatitis C: qualitative research with participants enrolled in a treatment trial in Ho Chi Minh City, Vietnam.平衡对丙型肝炎治疗的不确定性和主动性：在越南胡志明市参与治疗试验的参与者的定性研究。
Int J Qual Stud Health Well-being. 2022 Dec;17(1):2126602. doi: 10.1080/17482631.2022.2126602.
4
Feasibility, effectiveness and cost of a decentralized HCV care model among the general population in Delhi, India.印度德里普通人群中去中心化 HCV 护理模式的可行性、有效性和成本。
Liver Int. 2022 Mar;42(3):532-540. doi: 10.1111/liv.15112. Epub 2021 Nov 29.
5
Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India.印度初治基因型 1/4 慢性丙型肝炎患者中维生素 D 补充对持续病毒学应答的影响。
Indian J Med Res. 2018 Aug;148(2):200-206. doi: 10.4103/ijmr.IJMR_1295_15.
6
Chronic Hepatitis C: Do Generics Work as Well as Branded Drugs?慢性丙型肝炎：仿制药的效果与品牌药一样好吗？
J Clin Exp Hepatol. 2017 Sep;7(3):253-261. doi: 10.1016/j.jceh.2017.08.003. Epub 2017 Sep 23.
7
Why Should Viral Markers Be Mandatory in Ocular Surgeries: A Hospital Based Retrospective Study.为何眼部手术中病毒标志物应为强制性检测：一项基于医院的回顾性研究。
J Clin Diagn Res. 2016 Oct;10(10):LC09-LC11. doi: 10.7860/JCDR/2016/21386.8713. Epub 2016 Oct 1.
8
Combating the wrath of viral hepatitis in India.对抗印度病毒性肝炎的肆虐。
Indian J Med Res. 2016 Jul;144(1):1-5. doi: 10.4103/0971-5916.193275.
9
Tackling the Hepatitis C Disease Burden in Punjab, India.应对印度旁遮普邦的丙型肝炎疾病负担。
J Clin Exp Hepatol. 2016 Sep;6(3):224-232. doi: 10.1016/j.jceh.2016.09.005. Epub 2016 Sep 7.
10
Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C.基于特拉匹韦的三联疗法治疗慢性丙型肝炎复发相关因素的评估。
J Postgrad Med. 2016 Jan-Mar;62(1):20-5. doi: 10.4103/0022-3859.173191.
本文引用的文献
1
Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India.印度国家肝脏研究协会（INASL）丙肝特别工作组共识声明。第二部分：INASL关于印度丙肝管理的建议。
J Clin Exp Hepatol. 2014 Jun;4(2):117-40. doi: 10.1016/j.jceh.2014.06.001. Epub 2014 Jun 24.
2
Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part I: Status Report of HCV Infection in India.印度国家肝脏研究协会（INASL）丙型肝炎病毒特别工作组共识声明。第一部分：印度丙型肝炎病毒感染现状报告。
J Clin Exp Hepatol. 2014 Jun;4(2):106-16. doi: 10.1016/j.jceh.2014.05.006. Epub 2014 Jun 9.
3
Hepatitis C drugs not reaching poor.丙肝药物无法惠及贫困人口。
Nature. 2014 Apr 17;508(7496):295-6. doi: 10.1038/508295a.
4
Treating hepatitis C in lower-income countries.在低收入国家治疗丙型肝炎。
N Engl J Med. 2014 May 15;370(20):1869-71. doi: 10.1056/NEJMp1400160. Epub 2014 Apr 10.
5
Curing chronic hepatitis C--the arc of a medical triumph.治愈慢性丙型肝炎——医学胜利之路
N Engl J Med. 2014 Apr 24;370(17):1576-8. doi: 10.1056/NEJMp1400986. Epub 2014 Apr 10.
6
New hepatitis C therapies: the toolbox, strategies, and challenges.新型丙型肝炎治疗方法：工具包、策略和挑战。
Gastroenterology. 2014 May;146(5):1176-92. doi: 10.1053/j.gastro.2014.03.003. Epub 2014 Mar 12.
7
Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.在发展中国家用于大规模治疗获取项目的丙型肝炎直接抗病毒药物的最低生产成本。
Clin Infect Dis. 2014 Apr;58(7):928-36. doi: 10.1093/cid/ciu012. Epub 2014 Jan 6.
8
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.1990年和2010年20个年龄组中235种死因的全球和区域死亡率：全球疾病负担研究2010的系统分析
Lancet. 2012 Dec 15;380(9859):2095-128. doi: 10.1016/S0140-6736(12)61728-0.
9
Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence.全球丙型肝炎病毒感染的流行病学：特定年龄组丙型肝炎病毒抗体血清流行率的新估计。
Hepatology. 2013 Apr;57(4):1333-42. doi: 10.1002/hep.26141. Epub 2013 Feb 4.
10
Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges.用于慢性丙型肝炎预防和治疗的宿主靶向药物：前景与挑战。
J Hepatol. 2013 Feb;58(2):375-84. doi: 10.1016/j.jhep.2012.09.022. Epub 2012 Oct 4.
Zotero 插件